SPY441.40-4.34 -0.97%
DIA345.64-1.80 -0.52%
IXIC15,043.97-137.96 -0.91%

Xeris Pharmaceuticals Completes Enrollment in Phase 1 Trial of Hypothyroidism Treatment

MT Newswires · 09/01/2021 06:02

Please log in to view news